News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFellows' CornerFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesSponsoredVirtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
    • MS Advanced Practice Providers
  • Movement Disorders
    • Parkinson Disease
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
AANEM 2025|
AES 2025|
NSGC 2025
Advertisement

Kathleen Hawker, MD

Advertisement

Articles by Kathleen Hawker, MD

Kathleen Hawker, MD: Clinical Findings for Satralizumab in Treating NMOSD

ByKathleen Hawker, MD
June 9th 2020

The group medical director of neuroscience at Genentech spoke to the findings recently presented at the 6th Annual Meeting of the European Academy of Neurology.

Advertisement

Latest Updated Articles

  • Kathleen Hawker, MD: Clinical Findings for Satralizumab in Treating NMOSD
    Kathleen Hawker, MD: Clinical Findings for Satralizumab in Treating NMOSD

    Published: June 9th 2020 | Updated:



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Tolebrutinib Falls Short in Phase 3 PERSEUS Study, Forcing Decision to Redact Regulatory Submission

2

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis

3

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS

4

NDA Accepted for Narcolepsy Oxybate TRN-257, Gene Therapy ETX101 Early Promise in Dravet, Bexicaserin's Impact on Developmental Encephalopathies

5

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
HCP Live
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us